ClinicalTrials.gg
Not yet recruitingNCT07262008SMILEUpdated Dec 10, 2025

Sustained Mood Improvement With Laughing Gas Exposure

A Phase 3 interventional study of Inhalation of Nitrous oxide (Laughing gas) + intravenous saline and inhalation of %100 oxygen + intravenous midazolam in Major Depressive Disorder and Treatment Resistant Depression, sponsored by Women's College Hospital. Not yet recruiting at 5 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Women's College Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 312 studies in Depressive Disorder, Major with a site in Canada — 66 open to participants now, 82 under way, 12 of them phase 3. Depressive Disorder, Major · Canada.

Planned enrollment
101st of 284
120 · median 70
Started
2026
with 15 others
Phase 3
66 of 312
7 open now
Primary completion
2027-02
later than 42 of 81 live
Registered
298th of 312
by date

Among the 312 studies in Depressive Disorder, Major with a site in Canada, this one is the 101st largest by planned enrollment of the 284 interventional ones that give a count, is one of 16 that started in 2026, is one of 66 in phase 3, reaches primary completion later than 42 of the 81 other live ones, and was the 298th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

66 of the 312 studies in Depressive Disorder, Major with a site in Canada are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Depressive Disorder, Major with a site in Canada, or all of them as a file.
02

Study summary

Multi-centre, parallel group, blinded, 1:1 randomized controlled trial to determine the effect of nitrous oxide on reducing symptoms of depression in patients with treatment resistant depression.

Read the detailed description

SMILE is a multi-centre, parallel-group, blinded randomized controlled trial of 120 patients with treatment resistant depression. Consented eligible patients will be randomized to 1) Inhalation of Nitrous Oxide + Intravenous Saline (intervention Group)or 2) Inhalation of Oxygen + Intravenous Midazolam (Active Control Group). Participants will receive their respective study intervention once a week for four weeks for a total of four sessions. Follow-up visits will be conducted over the phone 2-weeks, 4-weeks, and 12-weeks following the last intervention visit. Questionnaires will be administered to assess change in depressive symptoms, function, and quality of life.

03

Conditions studied

  • Major Depressive Disorder
  • Treatment Resistant Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 65 years of age
  2. Meeting Diagnostic and Statistical Manual for Mental Disorders () criteria for Major Depressive Disorder (MDD)
  3. Current major depressive episode as confirmed by the Mini International Neuropsychiatric Interview (MINI) for DSM-5
  4. Experiencing moderate to severe depressive episodes, as defined by the Montgomery-Åsberg Depression Rating Scale (MADRS) > 21
  5. Failure of two trials of antidepressant therapy of adequate dose and duration, during the current depressive episode
  6. For women of , use of highly effective or double-barrier methods of . Abstinence is acceptable if it is the preferred and usual lifestyle of the female participant
  7. Capacity to provide .

Exclusion criteria

Exclusion Criteria:

  1. Acute suicidality defined as score > 4 on MADRS item 10
  2. Diagnosis of Bipolar Disorder
  3. Current substance abuse or dependence and/or history of alcohol abuse or dependence within the past year
  4. Dementia
  5. Current or lifetime history of schizophrenia or schizoaffective disorder
  6. Known history of or allergy to nitrous oxide, midazolam or any ingredients in the study formulations
  7. to receiving nitrous oxide (e.g. any condition where air is entrapped within a body and its expansion might be dangerous such as, pneumothorax, elevated intracranial pressure, air embolism, recent middle ear, vitreoretinal or bowel obstruction surgeries, etc.)
  8. Known chronic cobalamin or folate deficiency (e.g. signs of anemia or neurological symptoms, with plasma levels of homocysteine over 15 µmol/L and abnormal red blood cells and leukocytes on a complete blood count CBC) or current methotrexate use
  9. Contraindication to receiving the placebo midazolam (e.g. shock, chronic heart failure, , closed-angle glaucoma, renal failure, patients with limited pulmonary reserve or those with severe decline of vital signs)
  10. Daily use of centrally acting medicinal products, such as opioid agonists, (e.g. naloxone and naltrexone) morphine derivatives (e.g. oxycodone, hydrocodone, oxymorphone, codeine), benzodiazepines (e.g. diazepam, clonazepam, alprazolam) and/or other central nervous system depressants such as barbiturates (e.g. phenobarbital, pentobarbital, amobarbital) and alcohol within the past week.
  11. Pregnancy or breastfeeding
  12. Received electroconvulsive therapy within the past six months
  13. Received ketamine treatment within the past six months
  14. Received repetitive transcranial magnetic stimulation within the past six months
  15. Unwilling to maintain current antidepressant regimen.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Nitrous oxide+ intravenous Saline

    Drug: Inhalation of Nitrous oxide (Laughing gas) + intravenous saline

  • Active comparator
    Active Control Group

    100% oxygen+ intravenous midazolam

    Drug: inhalation of %100 oxygen + intravenous midazolam

Interventions

  • DrugInhalation of Nitrous oxide (Laughing gas) + intravenous saline

    Drug page: Nitrous OxideStudies of Nitrous OxideNitrous Oxide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nitrous oxide at an inspiratory concentration of 50% with concurrent intravenous saline (20ml) for one hour.

    Also known as: Nitrous oxide

  • Druginhalation of %100 oxygen + intravenous midazolam

    Drug page: MidazolamStudies of MidazolamMidazolam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Inspiration of 100% oxygen with concurrent intravenous midazolam (0.02mg/kg, up to 2 mg) for one hour.

    Also known as: Midazolam

06

What researchers measure

Primary outcomes

  1. Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score

    The MADRS is a 10-item clinician-rated scale used to assess the severity of depressive symptoms and to detect changes over time in response to treatment. It is commonly used in randomized controlled trials due to its sensitivity to change and strong psychometric properties. The MADRS is also recognized by regulatory and health technology assessment agencies, including the U.S. Food and Drug Administration (FDA) and the Canadian Agency for Drugs and Technologies in Health (CADTH), as an established measure for evaluating treatment efficacy in depression. Higher scores indicate worse outcomes and greater severity of depression.

    Time frame: Baseline to the 2-week follow-up (Visit 6 - Day 35).

Secondary outcomes

  1. Proportion of patients who achieved a response

    Defined as a 50% reduction in MADRS score between baseline and the 2- and 12-week follow-ups.

    Time frame: 2-week and 12-week follow-ups post last intervention visit

  2. Proportion of patients who achieved remission

    Defined as achieving both a response and a MADRS score \<10 at the 2- and 12-week follow-ups.

    Time frame: 2-week and 12-week follow-ups post last intervention visit

  3. Change in self-reported depressive symptoms

    Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR-16) Higher scores are associated with increased severity in depressive symptoms Total scores range from 0-27 Normal/No Depression 0-5 Mild Depression 6-10 Moderate Depression 11-15 Severe Depression 16-20 Very Severe Depression 21-27

    Time frame: 2-week and 12-week follow-ups post last intervention visit

  4. Change in cognitive function

    Assessed using the Digit Symbol Substitution Test (DSST) The Digit Symbol Substitution Test (DSST) measures processing speed, attention, and executive function by assessing a person's ability to quickly and accurately pair numbers with symbols according to a key. To score it, the total number of correct symbol-for-number substitutions completed within a timed period (typically 90-120 seconds) is counted. Higher scores indicate better performance.

    Time frame: 2-week and 12-week follow-ups post last intervention visit

  5. Change in functioning and disability

    Assessed using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) Total Score Range: 0-100 0 = No disability 100 = Full disability WHODAS 2.0 scores reflect overall functioning across six domains (cognition, mobility, self-care, getting along, life activities, and participation). Higher scores indicate greater functional impairment.

    Time frame: 2-week and 12-week follow-ups post last intervention visit

  6. Change in anxiety symptoms

    Assessed using the Generalized Anxiety Disorder 7-item scale (GAD-7) A GAD-7 score is interpreted based on its total score, with the range being 0-21, where higher scores indicate more severe anxiety. The standard interpretation is: 0-4 (minimal anxiety), 5-9 (mild anxiety), 10-14 (moderate anxiety), and 15-21 (severe anxiety)

    Time frame: 2-week and 12-week follow-ups post last intervention visit

  7. Change in quality of life

    Assessed using the EuroQoL 5-Dimension 5-Level scale (EQ-5D-5L) The EQ-5D-5L is a standardized, participant-reported measure of health-related quality of life. It assesses five dimensions-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-each rated across five levels of severity (no problems to extreme problems). Responses are converted into a single index score, typically ranging from \<0 (health states worse than death) to 1.0 (full health).

    Time frame: 2-week and 12-week follow-ups post last intervention visit

  8. Assessment of Safety via FIBSER Scale

    Safety outcomes will be assessed by evaluating adverse events in both general and specific terms using the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale. FIBSER ; higher score indicates worse outcomes. Clinical Relevance of Question 3: 0-2 = no changes needed; 3-4 = side effects should be addressed; 5-6 = change treatment.

    Time frame: Baseline to Week 12

07

Study locations

5 sites
08

References and documents

Publications

  • Ladha KS, Lee J, Mattina GF, Pazmino-Canizares J, Wijeysundera DN, Nezhad FG, Tassone VK, Adamsahib F, Lou W, Kennedy S, Bhat V; SMILE Study Investigators. Sustained mood improvement with laughing gas exposure (SMILE): a randomised, placebo-controlled pilot trial of nitrous oxide for treatment-resistant depression. BJPsych Open. 2025 Sep 12;11(5):e208. doi: 10.1192/bjo.2025.10823. PubMed 40936464 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Feb 2027, 12 months later.

Of 123 phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 36. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 3, 2025
StartEst.
Feb 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Sep 1, 2028
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07262008
Lead sponsor
Women's College Hospital
Collaborators
Anesthesia Clinical Trials Unit (Department of Anesthesia and Pain Management), University Health Network, Toronto, Sunnybrook Health Sciences Centre, Unity Health Toronto, Canadian Institutes of Health Research (CIHR)
Responsible party
Karim Ladha (MD MSc FRCPC, Women's College Hospital) — Principal investigator
First posted
Dec 3, 2025
Start date
Feb 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Dec 10, 2025

Study contacts

Anesthesia Clinical Trials Unit
Contact
actu@uhn.ca
416-340-4800 ext. 4221
Karim Ladha, MD
principal investigator · Women's College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitrous Oxide

Start the discussion